NUCALA ( DrugBank: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
44	多発血管炎性肉芽腫症	9
45	好酸球性多発血管炎性肉芽腫症	8

44. 多発血管炎性肉芽腫症

臨床試験数 : 98 / 薬物数 : 108 - (DrugBank : 28) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 81

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-005726-15-NL (EUCTR)	02/12/2022	15/09/2022	A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults wi ...	A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority stu ...	Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of c ...	Product Name: Depemokimab Product Code: GSK3511294 INN or Proposed INN: Depemokimab Trade Name: Nucala P ...	GlaxoSmithKline Research & Development Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	192	Phase 3	United States;Czechia;Finland;Spain;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hu ...
2	EUCTR2021-005726-15-HU (EUCTR)	12/07/2022	24/05/2022	A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults wi ...	A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority stu ...	Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of c ...	Product Name: Depemokimab Product Code: GSK3511294 INN or Proposed INN: Depemokimab Trade Name: Nucala P ...	GlaxoSmithKline Research & Development Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	192	Phase 3	United States;Czechia;Finland;Spain;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hu ...
3	NCT05353179 (ClinicalTrials.gov)	June 2022	11/4/2022	Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers	Phase I, Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of Pharmacokineti ...	Granulomatosis With Polyangiitis;Hemophagocytic Syndrome	Drug: Meperizumab injection;Drug: NUCALA®	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	NULL	Not yet recruiting	18 Years	55 Years	Male	88	Early Phase 1	China
4	EUCTR2021-005726-15-ES (EUCTR)	17/05/2022	04/03/2022	A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults wi ...	A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority stu ...	Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of c ...	Product Name: Depemokimab Product Code: GSK3511294 INN or Proposed INN: Depemokimab Trade Name: Nucala P ...	GlaxoSmithKline Research & Development Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	192	Phase 3	United States;Czechia;Finland;Spain;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Ca ...
5	EUCTR2019-001832-77-IT (EUCTR)	25/02/2020	15/06/2021	A study to evaluate if benralizumab compared to mepolizumab may be beneficial in the treatment of Eo ...	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...	Eosinophilic Granulomatosis with Polyangiitis (EGPA) MedDRA version: 20.1;Level: LLT;Classification ...	Trade Name: NUCALA Product Name: mepolizumab Product Code: [L04AC06] INN or Proposed INN: Mepolizumab Pr ...	ASTRAZENECA AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	France;United States;Canada;Belgium;Israel;Germany;United Kingdom;Japan;Italy
6	EUCTR2019-001832-77-DE (EUCTR)	15/01/2020	21/08/2019	Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab.	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...	Eosinophilic Granulomatosis with Polyangiitis (EGPA) MedDRA version: 20.1;Level: LLT;Classification ...	Trade Name: Fasenra Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab ...	AstraZeneca AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	France;United States;Canada;Belgium;Israel;Germany;United Kingdom;Italy;Japan
7	EUCTR2019-001832-77-FR (EUCTR)	23/12/2019	02/08/2019	A study to evaluate if benralizumab compared to mepolizumab may be beneficial in the treatment of Eo ...	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...	Eosinophilic Granulomatosis with Polyangiitis (EGPA);Therapeutic area: Diseases [C] - Respiratory Tr ...	Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive n ...	AstraZeneca AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	United States;France;Canada;Belgium;Israel;Germany;Japan;Italy;United Kingdom
8	EUCTR2019-001832-77-GB (EUCTR)	20/08/2019	22/10/2020	Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab.	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...	Eosinophilic Granulomatosis with Polyangiitis (EGPA);Therapeutic area: Diseases [C] - Respiratory Tr ...	Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive n ...	AstraZeneca AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	United States;France;Canada;Belgium;Israel;Germany;Japan;Italy;United Kingdom
9	EUCTR2012-004385-17-GB (EUCTR)	12/12/2013	30/10/2013	Study of mepolizumab versus placebo in addition to standard of care for the treatment of Eosinophili ...	A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepol ...	Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Th ...	Trade Name: Nucala Product Name: Mepolizumab Product Code: SB-240563 INN or Proposed INN: Mepolizumab Ot ...	GlaxoSmithKline Research & Development Ltd	NULL	Not Recruiting			Female: yes Male: yes	130	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;United States;Canada;Belgium;Spain;Germany;Japan;Italy;United Kingdom

First Previous1Next Last

先頭へ

45. 好酸球性多発血管炎性肉芽腫症

臨床試験数 : 31 / 薬物数 : 44 - (DrugBank : 18) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 101

diseases per page:

Showing 1 to 8 of 8 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-005726-15-NL (EUCTR)	02/12/2022	15/09/2022	A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults wi ...	A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority stu ...	Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of c ...	Product Name: Depemokimab Product Code: GSK3511294 INN or Proposed INN: Depemokimab Trade Name: Nucala P ...	GlaxoSmithKline Research & Development Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	192	Phase 3	United States;Czechia;Finland;Spain;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hu ...
2	EUCTR2021-005726-15-HU (EUCTR)	12/07/2022	24/05/2022	A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults wi ...	A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority stu ...	Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of c ...	Product Name: Depemokimab Product Code: GSK3511294 INN or Proposed INN: Depemokimab Trade Name: Nucala P ...	GlaxoSmithKline Research & Development Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	192	Phase 3	United States;Czechia;Finland;Spain;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hu ...
3	EUCTR2021-005726-15-ES (EUCTR)	17/05/2022	04/03/2022	A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults wi ...	A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority stu ...	Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of c ...	Product Name: Depemokimab Product Code: GSK3511294 INN or Proposed INN: Depemokimab Trade Name: Nucala P ...	GlaxoSmithKline Research & Development Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	192	Phase 3	United States;Czechia;Finland;Spain;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Ca ...
4	EUCTR2019-001832-77-IT (EUCTR)	25/02/2020	15/06/2021	A study to evaluate if benralizumab compared to mepolizumab may be beneficial in the treatment of Eo ...	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...	Eosinophilic Granulomatosis with Polyangiitis (EGPA) MedDRA version: 20.1;Level: LLT;Classification ...	Trade Name: NUCALA Product Name: mepolizumab Product Code: [L04AC06] INN or Proposed INN: Mepolizumab Pr ...	ASTRAZENECA AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	France;United States;Canada;Belgium;Israel;Germany;United Kingdom;Japan;Italy
5	EUCTR2019-001832-77-DE (EUCTR)	15/01/2020	21/08/2019	Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab.	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...	Eosinophilic Granulomatosis with Polyangiitis (EGPA) MedDRA version: 20.1;Level: LLT;Classification ...	Trade Name: Fasenra Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab ...	AstraZeneca AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	France;United States;Canada;Belgium;Israel;Germany;United Kingdom;Italy;Japan
6	EUCTR2019-001832-77-FR (EUCTR)	23/12/2019	02/08/2019	A study to evaluate if benralizumab compared to mepolizumab may be beneficial in the treatment of Eo ...	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...	Eosinophilic Granulomatosis with Polyangiitis (EGPA);Therapeutic area: Diseases [C] - Respiratory Tr ...	Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive n ...	AstraZeneca AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	United States;France;Canada;Belgium;Israel;Germany;Japan;Italy;United Kingdom
7	EUCTR2019-001832-77-GB (EUCTR)	20/08/2019	22/10/2020	Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab.	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...	Eosinophilic Granulomatosis with Polyangiitis (EGPA);Therapeutic area: Diseases [C] - Respiratory Tr ...	Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive n ...	AstraZeneca AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	United States;France;Canada;Belgium;Israel;Germany;Japan;Italy;United Kingdom
8	NCT03557060 (ClinicalTrials.gov)	June 25, 2018	4/6/2018	NUCALA® Special Drug Use Investigation (EGPA, Long-term)	NUCALA ® Subcutaneous Injection Special Drug Use Investigation (EGPA, Long-term)	Churg-Strauss Syndrome	Drug: Nucala	GlaxoSmithKline	NULL	Active, not recruiting	N/A	N/A	All	300		Japan

First Previous1Next Last

先頭へ